Perspective: Although opioid tapering can be challenging, helping patients to understand individualized reasons for tapering, encouraging patients to have input into the process, and assuring patients they would not be abandoned all appear to facilitate optimal communication about tapering.
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interviews. For clinic recordings, an audio recorder was placed in the exam room, with the research staff member waiting outside the room. Recorders were collected at the conclusion of each visit and arrangements were made for contacting the patient about recording his/her next PCP visit. After completing at least two PCP visits, the patient's qualitative interview was scheduled. PCPs were interviewed after all or most of their patients' visits had been recorded, based on availability. Part of the interview protocol for patients and PCPs included playing a portion of a recorded clinic visit pertaining to pain and/or opioid management, to elicit participants' perceptions of the communication in the visit. All interviews were one-on-one, face-to-face, and audio-recorded. All audio recordings (clinic visits and interviews) were transcribed, de-identified, and checked for accuracy.
Interviews. The project coordinator (MH), an experienced qualitative interviewer, conducted all interviews. We asked patients and PCPs about the patient-provider relationship, pain/opioid management, opioid monitoring practices, and policies/laws governing opioid prescribing.
Data Analysis. A total of 95 clinic visits (up to 3 per patient) and 31 (9 PCP, 22 patient) interviews were recorded and analyzed. The first author, working with two other experienced qualitative data analysts (NJ, MH), led data analysis, which consisted of an inductive approach using the method of constant comparison. 5, 21 This is an iterative process with two broad phases: open coding and focused coding. 5, 21 During open coding, team members read all transcripts analyzing them for common and recurrent themes. This step elucidated aspects of opioid management and tapering. During focused coding, analysts developed additional conceptual domains by describing comparisons between themes, within and between transcripts.
6 Throughout this process, procedures established in the literature on qualitative methods were employed to ensure rigor and validity. These procedures included practicing reflexivity (continually questioning interpretations, seeking answers in the data to verify or challenge interpretations, becoming aware of one's own preconceptions and biases), depth of description (seeking out the rich, particular details of participants' words), and searching for alternative explanations or interpretations of the data. 18, [20] [21] [22] All authors participated in final interpretations of the data.
RESULTS
Nine PCPs and 37 of their patients participated. PCPs ranged in age from 30-62 years. Seven
PCPs were White; one was Black, and one was Asian. Eight were female, and all PCPs were non-Hispanic.
Patients were aged 22-74 years (M=58; SD=10.4). Seventeen patients were Black, 15 were White, 1 was
American Indian/Alaskan Native, and the remainder did not provide race data. All patients were nonHispanic; 12 were male. See Table for demographics. One patient withdrew from the study after the first clinic visit, citing lack of time.
Notably, this study's purpose was to understand communication about opioid management for chronic pain, and tapering appeared as an emergent theme. Four themes revealed different aspects of patient-provider communication that appeared central to the tapering process: 1) explaining reasons for tapering; 2) negotiating the tapering plan; 3) managing difficult conversations; and 4) assuring patients that they will not be abandoned.
Explaining Reasons for Tapering
Both patients and PCPs emphasized the need for understanding individualized reasons for tapering, especially if patients were using their opioids as prescribed. In several clinic visits, PCPs explained in detail reasons for tapering, including risks and side effects of opioids. For example, the following PCP provided a long explanation of why she was tapering this patient, including emphasizing that it was not because of concerns of abuse or diversion. A short excerpt is below:
I don't have a concern with you abusing or selling them. I mean, we know each other and we know that's not an issue. The issue is that over time they stop working… the higher and higher doses of pain medications people are on, it can cause side effects, bad constipation, it can cause depression, it can cause decrease in your drive to breathe, and these are in people who are not trying to do anything wrong, they just want relief.
(Clinic: PCP3, Pt3)
However, as the following clinic excerpt illustrates, patients and PCPs did not always agree on the need to taper:
PCP: So what we were planning on doing is continuing to wean you… Patient: And my pain gets worse and worse and worse.
PCP:
But the oxycodone, that wasn't the thing that… Patient: They were helping me to move around, get more like it wasn't even so stiff and achy.
PCP: But it's just, it's not safe. It is just not safe.
Patient: Ok I understand that too, but I don't think it is fair to me and my pain.
We can try some stuff today, but an opiate or narcotic pain medication is not a safe option for you right now. (Clinic: Pt5, PCP2)
Frequently patients told us that they did not understand why their opioid doses were being reduced. Some patients said they had no discussions with their PCPs about reasons for tapering. Others described having conversations with their providers that addressed general reasons for tapering but did not apply to them specifically (e.g., addiction is a potential risk). In fact, many patients told us that they understood global risks such as addiction potential, but they did not believe that these risks applied to them personally, either because they were genuinely in pain, or because they were not engaging in aberrant behaviors (e.g. asking for early refills, taking more than prescribed, or losing their prescriptions). For example, one patient said, The argument about narcotics is sometimes difficult because patients look from their perspective. They are looking at it from an N of 1, right? And so they're thinking, especially because we have a lot of patients who've been on narcotics for years, "So I've taken this medicine, I've been fine for 10 years. It works for me…why in the world would you change it?" And from my point of view, you know, we're looking at millions of people and data (Interview: PCP5).
Another PCP stated more bluntly,
Everybody thinks they're unique and they're not gonna overdose, and they're not addicted, and they never did anything wrong, and they need their medicine, and they've never had any of those side effects, and [the opioid] helps them (Interview: PCP7).
In response to this disconnect between knowledge about opioid risks and its application to individual patients, some PCPs successfully tailored their messages about opioid tapering to their patients' individual circumstances. For example, the following PCP described how she helped a patient with pulmonary disease better understand why she was reducing her opioids:
We were able to very directly talk about the [opioid] medication's effects potentially on her respiratory system. So that was very clear to her. [I said], "Listen, you have a decreased respiratory drive. You are on oxygen. We don't want anything else to suppress that." So I think having that tangible, kind of helped her to buy into it, instead of abstractly talking. She really can see, I'm on oxygen and I don't really breathe well.
And then once we got her to two a day and she feels good, then she can, again, kind of buy into that (Interview: PCP2).
The following PCP took a similar approach in clinic with a patient by explaining how aging played an important role in the need to reduce opioids:
Just something to think about because it's gonna happen at some point. [ The opioid] is gonna build up in your system and cause you problems, so we might as well get ahead of it. I've been through this with other folks. You know you get older. You're a few years older than you were before, and the organs just don't work as quickly to break it down, and so you're still left in pain. It's tricky. It's really tricky 'cause you've still got the pain but we have to attack that in different ways because you've got this drug on board that will eventually likely cause you problems. (Clinic: PCP1, Pt7)
Negotiating the Tapering Plan
While helping patients understand the individual reasons that tapering was important, patient input in the tapering process also emerged as an important theme. Both patients and PCPs described a desire for patients to be given options and thereby have some control over the tapering process.
Sometimes patients and their PCPs were able to successfully negotiate tapering. Other times they believed the other person was not listening; thus, communication broke down.
One patient described a process of successful negotiation with her provider:
She put me down to 2 ½ [pills/day]. Then she said, okay, we'll go down to half a pill. I told her I didn't think that just two a day would do it, and she said okay, we'll try 2 ½, are you agreeable with that? I said that's fine. I mean, we can discuss stuff. It doesn't have to be a disagreement because we can talk about it. It's not an argument. We're two adults having a conversation, figuring out what to do (Interview: Pt3).
This patient's PCP described a similar process of collaboration:
I try to give them options. We could go down this month from four a day to three a day, or to three and a half a day, or we can switch from oxycodone to hydrocodone. So I try and give them different options and I think that has helped me actually get people more on board. These are the ways that we can do it together and then, I have really listened to people when I've been weaning a little bit and if they say, this is not working I'm in a lot of pain, I've gone back up for a little while and tried to figure out a different way to bring them down (Interview: PCP3).
In this patient's clinic visit, we see the provider giving the patient options:
Provider: Yeah, so you have the 7.5 [mg]. You're on the higher doses of them, so in trying to cut back, we could do a couple of things. We could cut back the numbers, the M A N U S C R I P T A C C E P T E D Another clinic excerpt with the same provider and a different patient also shows this provider's efforts to involve the patient:
Provider: I want to make sure that you're on board with this too. It was not only patients who felt they were not being heard. Providers, too, described trying to explain tapering and discuss options with patients, often without success:
It's really bad because they have one specific thing that they want and they aren't really listening, most of them, to the other options. Yet I've got the law, hospital policy, my own good judgment, and it's saying I can't just-I want to try and help you get better, but only under certain circumstances (Interview: PCP7).
Managing Difficult Conversations
As the above themes suggest, conveying understanding and negotiating about tapering were not always successful, and the result was conversations that could be contentious and frustrating. The following clinic visit involved a lengthy discussion about opioid tapering, including arguments and threats to obtain opioids elsewhere:
Patient: But, like it is not fair.
PCP:
Well, but my goal for you is to keep you safe and to also make sure that I'm not actually hurting you by giving you the medicines that I'm doing. For patients who are using their opioids as prescribed and believe they are doing well, conversations about tapering can be especially difficult, since it is not usual practice to discontinue a medication that appears beneficial. The same PCP as above explained: Although not all conversations were overtly contentious, situations when PCPs had trouble justifying, even to themselves, the reasons to taper a particular patient sometimes exacerbated the difficulty of these conversations. The following PCP described her own internal conflict about tapering an 85-year old patient for whom she was not sure tapering was appropriate:
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Sometimes I have to just check myself in terms of, you know, is this my issue? Is this just that I don't like the numbers? Because, there's data and we know that [opioids are] not good for elderly, but then people are also individuals…This guy seems to be thriving.
And so maybe he's one of the people I leave alone…But then I see him and I talk to him, and I'm like, I don't know, maybe [tapering] is the right thing. I think it's more of an internal conflict than a conflict when he's in the room. There's not arguing. It's more of, I
sort of ruminate on it (Interview: PCP 3).
PCPs also described conversations that went well. A typical example is the PCP who said, "The woman I had to wean, she accepted it. She said, 'you know, I don't think I did anything wrong. I used my 
Assuring Patients that They will not be Abandoned
An important part of productive opioid tapering conversations, both for patients and providers, was ensuring that patients did not feel abandoned during tapering. As PCP 7 said above, the relationship is an important factor in tapering discussions. PCPs frequently reassured patients that they would be with them through the entire tapering process, and sometimes even told patients that if the pain became intolerable, they could discuss increasing the opioid dose again for a time. This seemed to provide an important safety net for patients. For example, one patient said, "I knew she wasn't just going to take me completely off of [the opioids] because I would be miserable…She just said, 'We'll try this, but if you need to go back to where you were, I'll do that'." (Interview: Pt20)
PCPs frequently described reassuring patients that they would not experience tapering alone:
[Patients sometimes say], I'm not sure I believe this is gonna work…That's the vibes that they're giving. And I just try and reassure them that I hear them, how bad the pain is, and…what we do have to offer, and some kind of hope, and try and you know I want to work with you... and…If I've been able to build some rapport by really listening and asking lots of good questions and trying to be empathetic, then often they're [willing to]
give it a chance…Most of these people I've been taking care of for a long time, so there's at least that relationship, and they know I'm not going to cut them off (Interview: PCP7).
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Another PCP described a conversation in which she relied on the long relationship she has had with the patient:
She was nervous about [tapering] , and I said this is a trial, you know, I'm not leaving, I'm not going anywhere. You know I'm with you. We've been together a long time, so I'm not going to disappear on you (Interview: PCP1).
These sentiments were illustrated in clinic excerpts, such as the following when a patient's PCP said,
The hope would be next time to be done [tapering] . So, the hope is that this is your last prescription. Now, I'm not gonna leave you, you know, out to, what is it? Out to dry…I forgot the expression. So, you know, work with me and if things aren't working, then we can revisit that, okay? (Clinic: PCP3, Pt9)
More bluntly, one PCP reassured her patient in clinic, "I'm not gonna pull the rug out from under you.
It's not gonna happen, okay? Not gonna happen." (Clinic: PCP1, Pt7)
DISCUSSION
In response to widespread concerns about opioid-related harms, tapering has become common practice; however, despite the surge in tapering, we know little about how patients and their providers communicate about this process. Given that pain and opioid management are communicative activities and this communication is sometimes challenging, [22] [23] [24] 31 it is critical to learn more about how tapering occurs. These lessons learned will help to inform future clinical communication about tapering, to optimize patients' understanding of and experiences with tapering, and to avoid unintended negative consequences.
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In recorded clinic visits and individual interviews with patients and PCPs, four themes emerged related to opioid tapering: 1) Explaining reasons for tapering; 2) Negotiating the tapering plan; 3)
Managing difficult conversations; and 4) Assuring patients that they will not be abandoned. Both patients and PCPs recognized that patients needed to understand reasons for having tapering discussions. Patients acknowledged generally that opioids could be harmful and that some people misused them, but often did not see how this was applicable to them, because they legitimately had pain and were taking their medications as prescribed. Previous research has corroborated the notion that patients generally understand the risks of opioids, but most do not think that these risks apply to them. 12 PCPs acknowledged this gap in understanding, noting that patients only have their own experiences for perspective ("an N of 1"). These findings point to potential benefits of shifting the conversation about opioid tapering from the current opioid crisis, which is abstract and distant for patients, to a patient's own unique medical history and the particular risks that opioids can pose based on this history. Future research should seek to identify optimal ways for PCPs to frame messages about opioid tapering. Educational efforts should seek to help PCPs individualize opioid tapering to facilitate patients' understanding of tapering as an effort to protect their health, and not as punishment.
Involving patients in tapering was critical, both to patients and to PCPs. In an environment of state and institutionally mandated tapering, patients and providers often have little control over whether tapering happens. Nonetheless, patients expressed a desire to have input into these decisions, and many providers agreed and were willing to work with patients on details such as the rate of tapering. Unsurprisingly, breakdowns in communication still occurred. Patients described trying unsuccessfully to negotiate their tapering, and PCPs described patients who persistently resisted tapering efforts. Difficult interactions about pain are well-documented, 2, 10, 12, 18, 24, 31, 34 and widespread opioid tapering is likely to place additional strains on already difficult patient-provider relationships.
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When communication broke down, either because of disagreements on the tapering plan, lack of understanding about tapering, or other reasons, this often led to difficult conversations in which patients argued, or even threatened to obtain their opioids illegally. Some PCPs described the emotional toll of these conversations. Further exacerbating this difficulty, PCPs were not always convinced that opioid tapering was best for certain patients. Although this skepticism emerged in interviews, it did not manifest in clinical communication in this study. It is unclear why this was the case; one possible explanation is that institutional pressure for overall reductions in opioid doses superseded PCPs' doubts, leading them to remain silent. PCPs have previously described pain management as challenging. 10, 24 Breakdowns in communication about tapering can exacerbate these challenges, particularly when PCPs themselves are unconvinced that tapering is appropriate for some patients. Unvoiced provider skepticism about opioid tapering for particular patients, and how providers approach this skepticism, is an important area for further research. Assuring patients that their PCPs would not abandon them during opioid tapering was identified as critical, by both patients and PCPs. Beyond the general, abstract concept of "trust" that is often discussed, patients and providers pointed to non-abandonment as key for productive communication about opioid tapering. Patients needed to know that their providers were not going to reduce their opioids and then disappear. PCPs were acutely aware of this need and repeatedly responded with reassurances that they would not abandon their patients. Some PCPs even expressed a willingness to increase an opioid dose temporarily if a patient was having difficulty adjusting to a lower dose. This notion of non-abandonment expands on the important role of the patient-provider relationship in chronic pain care. 24, 31 Strong relationships may be especially valuable when difficult decisions about opioid treatment are made. For example, when doctors demonstrated genuine concern for their patients' health and wellbeing, patients with chronic pain seemed more willing to accept decisions to limit or deny opioids. 22 In a recent study involving interviews with patients being tapered off of opioids, Frank and colleagues 13 found that patients believed having a trusted physician was essential.
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Studies have shown that when patients and their PCPs have similar concerns about opioids, they can approach these concerns collaboratively. 4, 16, 23 Collaboration and trust are especially important as nonopioid treatments are explored and as patients face fears of opioid withdrawal or uncontrolled pain.
Indeed, in Frank and colleagues' 13 interviews, patients revealed that withdrawal and uncontrolled pain were major barriers to opioid tapering. Further corroborating the importance of provider support during opioid tapering, a recent pilot study found that patients randomized to a taper support intervention involving psychiatric consultation and weekly meetings with a physician assistant showed greater improvement on pain interference, pain self-efficacy, and perceived opioid problems, than control patients. 30 Support, further elaborated as non-abandonment in the current study, appears to be a critical element of communication about opioid tapering.
Findings from this study add to the small but growing body of research revealing how patients and providers experience opioid tapering. In Frank and colleagues' 13 recent study involving interviews with patients at various stages of tapering, patients noted that their current pain was more urgent than potential future risks of opioids, expressed skepticism about the efficacy of non-opioid analgesics and fear of withdrawal, and described the central role of social support during tapering. The current study illuminates the communicative processes surrounding opioid tapering, exploring both patients' and PCPs' perspectives, as well as actual clinical communication. Through these multiple data sources, the patient-provider relationship during tapering emerges as fundamental. Indeed, the current study not only underscores the centrality of this relationship, but illuminates critical aspects of this relationship that appear important to patients and providers during tapering. Providers have pivotal roles in helping patients to understand why they are being tapered, giving them input into the process, and assuring them that they will not be abandoned while their doses are being reduced. This study has a number of strengths. Qualitative methods enable the capture of rich, particular details of participant experiences that may not be available through other methods. 6 In addition, because interview accounts by themselves are subject to recall bias and are shaped by participants' own experiences and perspectives, combining interviews of both patients and providers with analysis of actual clinical communication allows for the fullest exploration of communication related to opioid tapering, providing insights from multiple perspectives.
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Communication about chronic pain and its treatment is challenging, particularly when opioids are involved. Clearly, these communicative challenges can be exacerbated when patients are being tapered down or off opioids, oftentimes against their wishes. The current study highlights some important clinical implications as more patients experience tapering. Specifically, if clinicians tailor their messages to help each patient understand why tapering may be beneficial to them, based on their own unique circumstances and medical history, conversations about tapering could be more productive. In addition, our findings indicate that encouraging patients to have input into the tapering process, even if it is simply the rate of tapering, can help patients feel as if they have some control over their treatment.
Finally, while the centrality of the patient-provider relationship in pain management is recognized, the specific notion of non-abandonment emerged as critically important to both patients and providers. 
